Tatva Chin Pharm Chem Ltd
NSE: TATVA · Specialty Chemicals · sector
₹1,567.50NSE close 2026-10-26
Key numbers
Market cap₹3,667 cr
Price₹1,567.50
52w high / low₹2,114 / ₹1,044
P/E58.3xSector median 22.6x
P/B4.5xSector median 2.6x
Book value₹348.3
Dividend yield0.06%Sector median 0.60%
ROE8.0%Sector median 10.6%
ROCE9.2%Sector median 12.9%
OPM19.3%Sector median 12.1%
Debt / equity0.21xSector median 0.18x
EV/EBITDA30.5xSector median 15.1x
Interest cover13.5x
Current ratio1.59x
Sales growth 3y+6.1%Sector median +5.0%
Profit growth 3y-2.6%Sector median +0.9%
PEG–
Last 12 months to Sep 2026, Consolidated. "Sector median" = middle value of 107 companies in Specialty Chemicals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹9 cr vs borrowings ₹120 cr (FY26): borrowings are higher by ₹112 cr.
- Operating profit covered interest 13.5x in the last 12 months.
- Operating cash flow was below net profit in 3 of the last 5 years (FY26, FY23, FY22).
- Revenue was higher than a year earlier in 4 of the last 4 quarters.
- Other income was 9% of net profit in the last 12 months.
- Debtor days went from 65 (FY24) to 86 (FY26).
- Dividend paid in 4 of the last 5 financial years.
- Price ₹1,567.50 on 2026-10-26: -25.8% from the 52-week high, +50.1% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹1,944.00 · low ₹649.30
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 86 | 108 | 117 | 124 | 131 | 134 | 167 | 217 |
| EBITDA | 7 | 9 | 17 | 22 | 25 | 28 | 31 | 41 |
| OPM % | 8.2% | 8.3% | 14.8% | 18.0% | 19.4% | 21.0% | 18.5% | 18.7% |
| Other income | 0 | 1 | 1 | 1 | 2 | -0 | 3 | 2 |
| Net profit | 0 | 1 | 7 | 10 | 15 | 10 | 16 | 21 |
| EPS (₹) | 0.06 | 0.44 | 2.84 | 4.24 | 6.49 | 4.41 | 6.83 | 9.17 |
| Revenue YoY | +52.9% | +24.4% | +43.0% | +75.9% | ||||
| Profit YoY | +10,728.6% | +901.9% | +140.3% | +116.2% |
Consolidated figures where filed. Latest quarter Sep 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 434 | 424 | 394 | 383 | 506 | 650 |
| EBITDA | 108 | 57 | 68 | 34 | 93 | 125 |
| Net profit | 96 | 45 | 30 | 6 | 42 | 63 |
| EPS (₹) | 44.59 | 20.52 | 13.26 | 2.44 | 17.98 | 26.90 |
| Revenue growth | -2.3% | -7.1% | -2.7% | +32.2% | +49.7% | |
| Profit growth | -52.6% | -33.3% | -81.2% | +636.4% | +254.8% | |
| Dividend / share (₹) | – | 2.00 | 2.00 | 2.00 | 1.00 |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +6.1% | – | +49.7% |
| Net profit | -2.6% | – | +254.7% |
| EPS | -4.3% | – | – |
| Share price | – | +39.9% (2y) | +34.3% |
Balance sheet
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Shareholders' equity | – | 515 | 737 | 739 | 782 |
| Borrowings | – | 170 | 14 | 36 | 120 |
| Cash & equivalents | – | 45 | 48 | 14 | 9 |
| Total assets | – | 756 | 819 | 836 | 1,004 |
| Fixed assets | – | 196 | 427 | 526 | 604 |
| Capital work in progress | – | 231 | 73 | 22 | 23 |
| Investments | – | 0 | 0 | 0 | 4 |
| Receivables | – | 84 | 70 | 83 | 119 |
| Inventory | – | 162 | 153 | 134 | 196 |
| Payables | – | 32 | 45 | 33 | 58 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | 20 | 28 | 98 | 25 | 31 |
| Cash from investing | -197 | -101 | -121 | -65 | -116 |
| Cash from financing | 235 | 38 | 31 | 17 | 79 |
| Capex | 89 | 203 | 129 | 76 | 114 |
| Free cash flow | -69 | -175 | -30 | -52 | -82 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ROE % | – | 8.8% | 4.1% | 0.8% | 5.4% |
| ROCE % | – | 7.8% | 6.7% | 1.1% | 6.6% |
| Debtor days | – | 73 | 65 | 79 | 86 |
| Inventory days | – | 262 | 320 | 246 | 319 |
| Payable days | – | 52 | 94 | 60 | 95 |
| Cash conversion cycle (days) | – | 283 | 291 | 265 | 310 |
| Working capital days | – | 67 | 202 | 161 | 98 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 72.02% |
| FIIs | 4.38% |
| DIIs | 3.21% |
| of which Mutual funds | 2.87% |
| Government | 0.00% |
| Public (non-institutions) | 20.39% |
| Quarter | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 72.02% | 72.02% | 72.02% | 72.02% | 72.02% | 72.02% | 72.02% | 72.02% |
| Promoter group | % |
|---|---|
| Shekhar Rasiklal Somani | 23.07% |
| Chintan Nitinkumar Shah | 20.94% |
| Ajay Mansukhlal Patel | 20.16% |
| Priti Ajay Patel | 3.85% |
| Chintan N Shah (HUF) | 1.91% |
| Shital Chintan Shah | 0.99% |
| Kajalben Shekharkumar Somani | 0.93% |
| Darshana Nitinkumar Shah | 0.17% |
| Shitalbhai Rasiklal Somani | 0.00% |
| Somani Samir Rasiklal | 0.00% |
| Anushka Chintan Shah | 0.00% |
| Archana Chandravadan Shah | 0.00% |
| Aryan Shekhar Somani | 0.00% |
| Bharti Kirit Shah | 0.00% |
| Dharmeshkumar Mansukhlal Patel | 0.00% |
| Public holders above 1% | % |
|---|---|
| Goldman Sachs Funds - Goldman Sachs India Equity Portfolio | 2.59% |
| Nippon Life India Trustee Ltd-A/C Nippon India Elss Tax Saver Fund | 2.21% |
| Mukul Mahavir Agrawal | 2.14% |
62,888 shareholders. Pledged: – of promoter shares.
Peers in Specialty Chemicals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| PIDILITIND | ₹1,50,431 cr | 56.8x | 13.9x | 25.7% | 33.4% | 24.5% | +7.4% | 1.01% |
| FLUOROCHEM | ₹46,168 cr | 75.4x | 5.9x | 8.1% | 10.0% | 25.6% | -4.2% | 0.07% |
| NAVINFLUOR | ₹39,306 cr | 49.7x | 9.9x | 23.9% | 22.2% | 33.7% | +16.8% | 0.18% |
| DEEPAKNTR | ₹19,676 cr | 25.1x | 3.4x | 14.0% | 15.3% | 15.4% | -0.4% | 0.52% |
| AETHER | ₹19,529 cr | 82.8x | 8.0x | 10.1% | 11.4% | 30.9% | +21.2% | – |
| ATUL | ₹15,762 cr | 19.8x | 2.5x | 11.9% | 16.9% | 17.9% | +7.9% | 0.47% |
| AARTIIND | ₹15,539 cr | 29.3x | 2.6x | 9.2% | 8.0% | 14.9% | +7.8% | 0.24% |
| FINEORG | ₹15,328 cr | 35.0x | 5.8x | 17.7% | 21.3% | 21.7% | -7.8% | 0.22% |
| BASF | ₹13,174 cr | 20.5x | 3.3x | 16.9% | 22.0% | 5.9% | +3.1% | 0.66% |
| TATVA | ₹3,667 cr | 58.3x | 4.5x | 8.0% | 9.2% | 19.3% | +6.1% | 0.06% |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-09-11 | Dividend | Dividend - Rs 2 Per Share |
| 2025-09-12 | Dividend | Dividend - Re 1 Per Share |
| 2024-09-06 | Dividend | Dividend - Rs 2 Per Share |
| 2024-09-06 | Other | Annual General Meeting |
| 2023-09-08 | Dividend | Dividend - Rs 2 Per Share |
| 2023-09-08 | Other | Annual General Meeting |
| 2022-09-08 | Other | Annual General Meeting |
| 2022-09-08 | Dividend | Dividend - Rs 2 Per Share |
| 2021-09-17 | Other | Annual General Meeting |
Documents
- Annual report FY26
- Annual report FY25
- Annual report FY24
- Annual report FY23
- Annual report FY22
- Announcements NSE filings
- BRSR FY26
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
- Specialty Chemicals: Manufacturing of specialty chemical with diverse portfolio of Structure Directing Agents, Phase Transfer Catalysts, Electrolyte Salts and Solutions and Pharmaceutical and Agrochemical Intermediates and Other Specialty Chemicals
| Sector | Commodities |
| Industry | Specialty Chemicals |
| Sub-industry | Specialty Chemicals |
| Symbol | TATVA |
| BSE code | 543321 |
| ISIN | INE0GK401011 |
| Face value | ₹10.0 |
| Incorporated | 1996-06-12 |
| Website | www.tatvachintan.com |
| Plants (India / abroad) | 2 / 0 |
From the company's filings (BRSR FY26).
Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.